Related Experiment Video
Updated: Apr 17, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Risk factors for treatment failure of drug-resistant pulmonary tuberculosis: results from a two-decade data analysis
Karolina Kėvelaitienė1,2, Roma Puronaitė3, Valerija Edita Davidavičienė4
1Institute of Clinical Medicine, Clinic of Chest Diseases, Immunology and Allergology, Vilnius University Faculty of Medicine, Vilnius, Lithuania.
Background:
Drug-resistant tuberculosis (DR-TB) remains a major public health challenge worldwide, particularly in Eastern Europe, where high disease burden and complex treatment regimens contribute to suboptimal outcomes. Lithuania has historically reported high rates of pulmonary DR-TB; however, data on long-term treatment outcomes and their determinants over extended periods are limited. This study evaluated long-term treatment outcomes among adults with pulmonary DR-TB in Lithuania over a 22-year period and assessed associations between treatment outcomes, individual risk factors, and temporal trends.
Methods:
A retrospective cohort analysis was conducted using data from the National Tuberculosis Information System for 2000-2021. The study included 5,761 adults with DR-TB, categorized into three periods: Period I (2000-2007), Period II (2008-2015), and Period III (2016-2021). Treatment outcomes were classified as successful (treatment completion with recovery) or unsuccessful [treatment failure, progression to chronic TB, death before completion, or transition from multidrug-resistant tuberculosis (MDR-TB) to extensively drug-resistant tuberculosis (XDR-TB)]. Associations between outcomes and risk factors such as smoking, alcohol and substance use, comorbidities, and sociodemographic variables were examined using multivariate analysis.
Results:
Treatment success rates increased steadily across periods (66.2%, 68.5%, and 79.5%), while mortality rates declined (30.7%, 29.5%, and 20.1%). Non-lethal treatment failure rates decreased markedly (3.0%, 2.0%, and 0.3%). Treatment failure was significantly associated with low body mass index, male gender, unemployment, homelessness, tobacco and alcohol use, substance abuse, and comorbidities including cancer, cardiovascular and chronic lung disease, diabetes mellitus, human immunodeficiency virus (HIV) infection, and renal failure.
Conclusions:
Treatment outcomes of DR-TB in Lithuania have shown improvement over a 22-year period. Successful treatment outcomes were strongly influenced by a combination of clinical, behavioral, and socioeconomic factors, underscoring the complexity of DR-TB management. The relative importance of these components may vary for each individual patient. Incorporating multifaceted strategies, such as psychological support, social assistance (including access to food and shelter), and employment opportunities, into the national DR-TB control framework could enhance health system responsiveness and reduce inequities in care.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Treatment Resistant Cancers

